The Next Trade Alert Goes Live in Less Than 48 Hours — Here’s How to Get in on It!

The countdown begins.

Dear Loyal Reader, Biotech can create explosive opportunities to profit — when you have the right research. Like the research behind Paul's next BIG biotech trade alert he's releasing THIS THURSDAY. This pick has the same potential as some of Extreme Fortunes' heaviest hitters in this sector. I'm talking about stocks such as: • Stemline Therapeutics, which handed readers a 191% gain in just 35 days. • Immunomedics, which shot up 431% in under 12 months. • And ArQule, which soared 443% in a short 18 months… What Paul's next play has in common with these three stocks is they're each tied to what's called a "biotech takeover." It's when one company gets taken over by another — an event that could send the stock surging higher in just one day! However, what sets this new biotech ahead of the rest is that it's weeks away from potentially receiving FDA approval for its drug — a drug 60% of doctors plan to recommend as a "top pick." This is an opportunity you don't want to miss. Click here now and learn how to secure your spot in Extreme Fortunes to prepare yourself for Thursday's trade alert! Regards, Tamara Barkhanoy Investment Research Analyst, Banyan Hill Publishing   (c) 2021 Banyan Hill Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 866-584-4096) Legal Notice The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: http://banyanhill.com/contact-us Remove your email from this list: Click here to Unsubscribe